G
Ganymed Pharmaceuticals
Biopharmaceutical company that focuses on the development of therapeutic drugs for the treatment of solid cancers
About Ganymed Pharmaceuticals
Ganymed Pharmaceuticals AG was a biopharmaceutical company that focused on the development of a new class of therapeutic antibodies to fight cancer. The company was established in 2001 as a spin-off from the Universities of Mainz and Zurich, founded by Dr. Ugur Sahin, Dr. Özlem Türeci, and Professor Christoph Huber. The founders' extensive background in immunology and cancer research at the University of Mainz was instrumental in shaping the company's scientific direction. Dr. Sahin and Dr. Türeci, a husband-and-wife team, leveraged their deep understanding of the human immune system's potential to identify novel cancer targets. This scientific foundation led to the creation of Ganymed's pipeline of Ideal Monoclonal Antibodies (IMABs), which were designed to bind to specific proteins on tumor cells.
The company's primary business was centered on the discovery and clinical development of these highly selective antibodies. Ganymed's most advanced product candidate was Claudiximab, also known as IMAB362, which targeted the tight junction protein Claudin-18.2. This protein is found in approximately 80% of gastroesophageal adenocarcinomas, as well as in a variety of other solid tumors, but is largely absent from healthy tissues, offering a precise target for therapy. In clinical trials, Claudiximab demonstrated a significant extension in both median progression-free survival and median overall survival for patients with advanced gastroesophageal cancer. Ganymed's business model was typical for a clinical-stage biotech firm, focusing on research and development with the goal of bringing a product to market, often through a partnership or acquisition by a larger pharmaceutical company.
A pivotal milestone in Ganymed's history occurred in October 2016 when it was acquired by Astellas Pharma Inc. for a total potential consideration of up to €1.282 billion. The deal included an upfront payment of €422 million, with an additional up to €860 million in milestone payments contingent on the progress of Claudiximab. At the time, this represented the largest-ever transaction for a privately-owned biotechnology company in Germany, underscoring the significant value placed on Ganymed's lead asset and its underlying technology platform. The acquisition provided Astellas with a late-stage asset that had the potential to become a cornerstone of its oncology portfolio.
Source: Dealroom company dataAt a glance
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Ganymed Pharmaceuticals in the Mainz ecosystem
The Ganymed Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- NVNextech Venture
Landesbank Baden Württemberg
Future Capital
Series B and later2 investors entered at this stage
VI Partners- FGFCPB Gany GmbH
Source: Dealroom Talent Intelligence.
Global footprint
Patents
42 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ganymed Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ganymed Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


